Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours

PHASE2CompletedINTERVENTIONAL
Enrollment

129

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

October 31, 2013

Study Completion Date

August 31, 2015

Conditions
NeuroblastomaBrain TumorsSolid Tumors
Interventions
DRUG

Temozolomide/Hycamtin (Topotecan)

"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg~Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg~Patients receive during 5 days (Day 1 to Day 5):~Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"

Trial Locations (1)

94805

Institut Gustave Roussy, Villejuif

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

St. Anna Kinderkrebsforschung

OTHER

collaborator

Catholic University of the Sacred Heart

OTHER

collaborator

Erasmus Medical Center

OTHER

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER